-+ 0.00%
-+ 0.00%
-+ 0.00%

Citigroup Downgrades Amicus Therapeutics to Neutral, Lowers Price Target to $14.5

Benzinga·12/22/2025 13:37:20
語音播報
Citigroup analyst Samantha Semenkow downgrades Amicus Therapeutics (NASDAQ:FOLD) from Buy to Neutral and lowers the price target from $17 to $14.5.